Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE-PAIN psilocybin pilot trial for chemotherapy-induced neuropathic pain
NL-OMON60161Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin in chronic neuropathic pain and chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Recruitment and retention feasibility, Patient expectancy and 5 more. Started Oct 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
chronic neuropathic painchemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NL-OMON60161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60161.